Pluristem Therapeutics Approved For Dual Listing On The Tel Aviv Stock Exchange (TASE)

• Company Anticipates Joining four of TASE's Indexes
• Pluristem will open trading on the TASE on December 19 and will host a welcoming ceremony for investors and a press conference for journalists following the market opening

HAIFA, Israel, Dec. 12, 2010 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI), today announced that the Tel-Aviv Stock Exchange ("TASE") has approved the dual listing of the Company's shares of common stock on the TASE beginning at market open on December 19, 2010, under the ticker symbol PLTR.

The Company also announced today that, based upon Pluristem's current market capitalization, it expects its shares to be subject to inclusion in four TASE equity indexes: Tel-Tech, TA Composite, MidCap TA and Biomed.

"Pluristem is very proud to be listing its shares on the TASE, allowing us to address the great interest among local institutional investors and strategic partners to our solutions and technology platform," said Zami Aberman, CEO of Pluristem. "Listing on the TASE is an important part of the Company's vision of growing the Israeli economy through the country's pharmaceutical industry, and while Pluristem is the first stem-cell company to list on the TASE, we look forward to being joined by other companies in the near future."

Mr. Aberman; Prof. Edwin Horwitz, President of the International Society for Cellular Therapy and Chairman of Pluristem's Scientific Advisory Board; and Mr. Jason Kolbert, senior biotechnology analyst and Managing Director at National Securities, will speak at an investors conference following the market opening and will be available to answer questions.

In September 2010, Pluristem reported that data from clinical trials show the Company's placenta-derived cell therapy, PLX-PAD, is potentially safe and improves quality of life as well as other efficacy measurements in patients with Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD).